• Severe left CDH – observed to expected lung/head ratio <30%
• Severe right CDH – observed to expected lung/head ratio <45%

Gestational age:

• FETO at 27-29 weeks; balloon removal by 35 weeks’ gestation

Outcomes:

• Single-Center Outcome of Fetoscopic Tracheal Balloon Occlusion for Severe Congenital Diaphragmatic Hernia

Additional information:

• Webinar: Management Advances for Congenital Diaphragmatic Hernia—Integrating Fetal and Postnatal Care

• For suspected fetal anemia with elevated MCA PSV or fetal hydrops
• Stage II-IV Twin anemia polycythemia sequence (TAPS)
• Congenital hemoglobinopathy (Hemoglobin Barts disease)

Gestational age:

•  16-35 weeks’ gestation

Outcomes:

• The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry

Additional information:

• Webinar: Fetal Anemia: New Frontiers of Evaluation and Management

• For stage I-IV Twin–Twin Transfusion Syndrome (TAPS)
• Stage II-IV Twin Anemia Polycythemia sequence (TAPS)

Gestational age:

• 16-28 weeks’ gestation

Outcomes:

• Stage-based recipient and donor outcome in twin-to-twin transfusion syndrome treated by fetoscopic laser surgery using Solomon technique

Additional information:

• Video: Fetoscopic Laser Surgery Outcomes for Twin-to-Twin Transfusion Syndrome

• Isolated MMC upper level T-1 to S-1
• Hindbrain herniation
• Fetal kyphosis <30 degrees

Gestational age:

•  22-26 weeks’ gestation

Outcomes:

• Experience of 300 cases of prenatal fetoscopic open spina bifida repair: report of the International Fetoscopic Neural Tube Defect Repair Consortium

• Lower urinary tract obstruction with preserved renal function and progressive oligohydramnios
• Fetal hydrothorax
• Severe fetal cystic lung malformations

Gestational age:

• 22-32 weeks’ gestation

• Anhydramnios due to early gestational fetal renal disease or renal agenesis 

Outcomes:

• Comparison of Serial Amnioinfusion Strategies for Isolated Early-Onset Fetal Renal Anhydramnios
• Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis: The Renal Anhydramnios Fetal Therapy Trial

• Fetal VOG at high risk for fetal or neonatal decompensation
• No brain parenchymal damage
• < 8 mm width of the draining sinus on fetal MRI

Gestational age:

• ~26 - 33 weeks’ gestation

Additional information:

• Webinar: Vascular Abnormalities of the Fetal Brain: Fetal & Post-Natal Management and Treatment

• Amniotic band resection
• Umbilical cord transection
• Selective reduction
• Fetal / placental tumor ablation
• Microwave ablation procedures

• Type II or III vasa previa with 80% primary placental mass

• Eligibility evaluation at 28 weeks’ gestation

Gestational age:

• 30-32 weeks’ gestation

• Fetal sacrococcygeal teratoma with fetal hydrops
• Giant CPAM with fetal hydrops unresponsive to conventional therapy
• Fetal tumors

Gestational age:

• 28-32 weeks’ gestation

• Fetal airway obstruction

Gestational age:

• 35-38 weeks’ gestation

• Critical aortic stenosis with preserved left ventricular function

• Antiarrhythmic treatment of fetal cardiac arrhythmias
• Fetal tumors
• Trikafta for fetal cystic fibrosis
• Risdiplam for fetal spinal muscular atrophy type 1
• Iv Immunoglobulin (ivIG) therapy for alloimmune thrombocytopenia
• ivIG therapy for gestational autoimmune fetal liver disease (GALD)
• Nipocalimab for severe fetal hemolytic anemia